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Abstract
Purpose The myofibroblast, a contractile fibroblastic cell
expressing α-smooth muscle actin (α-SMA), has been
reported to play a role in ligament healing. The aim of this
study was to evaluate the feasibility of transplanting culture-
derived myofibroblasts in injured rabbit medial collateral
ligaments (MCL) and in intact anterior cruciate ligaments
(ACL).
Methods Fibroblasts isolated from the iliotibial band were
cultured in the presence of transforming growth factor beta-
1 (TGF-β1) for five days and analysed for α-SMA expres-
sion. In a concentration of TGF-β1≥10 ng/ml, the differen-
tiation rate into myofibroblast was 90%. After labelling with
PKH26, α-SMA -positive cells were transplanted in intact
ACL and in injured MCL of ten rabbits.
Results Survival of PKH-26+cells was seen in all intact and
damaged ligaments one day after injection. The density of
PKH-26+cells had decreased at seven days postinjection in
both ligaments. Double-positive PKH-26+/α-SMA+ cells
were only observed in injured MCL at seven days postin-
jection. Moreover, we found that genetically modified fibro-
blasts differentiate into myofibroblasts and can be
transplanted into ligaments.
Conclusions Our data demonstrate that culture-born myofi-
broblasts survive and maintain α-SMA expression up to one
week after transplantation. This study provides the first
insight into the feasibility of transplanted mechanically
active cells for ligament reconstruction.
Introduction
Ligament injuries are encountered frequently in orthopae-
dics and, if severe, can result in residual laxity, further
injury, joint pain and ultimately osteoarthritis. Despite the
availability of several therapeutic tools that help repair
ligament injuries [1], the healing process results, in most
cases—e.g. after anterior cruciate ligament (ACL) injury—
in a structure with mechanical properties inferior to those of
the native ligament [2–4]. Thus, much effort has been made
to improve and optimise the healing environment of injured
ligaments [5]. The use of cells as biological vehicles [6–10]
or of growth factors [11, 12] has been shown to enhance
ligament healing. Recently, the use of a bioactive collagen-
based scaffold infiltrated with platelets has yielded a
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positive effect on the healing of an ACL graft [13]. These
data emphasise the importance of cellular and molecular
mechanisms in the process of ligament healing and more
generally in the field of regenerative orthopaedics [14].
Myofibroblasts, identified as α-smooth muscle actin (α-
SMA)-positive fibroblasts [15, 16], have been observed in
normal and healing tendons [17, 18] [19] and in the intact
and injured human ACL [20–22]. They contribute substan-
tially to the contractile phase of MCL healing, allowing
recovery of its original length [23]. We previously demon-
strated that myofibroblasts and transforming growth factor
beta-R1 (TGF-β-RI) appear in the early phase of the MCL
healing process, similarly to that occurring during wound
healing [24]. The study reported here investigates whether
primary isolated rabbit fibroblasts can differentiate into
myofibroblasts in vitro and whether these cells can be trans-
planted into intact and injured ligaments. Data demonstrate
that culture-derived myofibroblasts transplanted in rabbit
ligaments, survive and maintain α-SMA expression up to
seven days after injection. These results emphasise the po-
tential of such cells to improve ligament healing after injury.
Material and methods
Cell culture
Rabbit fibroblasts were isolated from the iliotibial band
(ITB) and amplified on gelatine-coated dishes (NalgeNunc,
Rochester, NY, USA) at 37°C, 7% CO2 in Dulbecco’s
modified Eagle’s medium (DMEM) (Invitrogen, Basel,
Switzerland) containing 10% foetal calf serum (FCS)
(Readysystem, Kibbuth Beth Halmek, Israel) and 1% penicil-
lin/streptomycin (Invitrogen). The differentiation into myofi-
broblasts was induced by incubating primary fibroblasts for
five days in DMEM 10% FCS containing 0.1, 1 or 10 ng/ml
TGF-β1 (R&D systems Inc., Minneapolis, MN, USA).
GFP lentivirus production
A three-plasmid expression system was used to generate
second-generation lentiviral vectors by transient transfec-
tion, as previously described [25]. Rabbit fibroblasts were
transduced with the lentivirus green fluorescent protein
(GFP) at multiplicity of infection (MOI) of 10 before
TGF-β1 stimulation.
Induction of MCL injury and myofibroblast transplantation
Animal studies described in this study were approved by the
Ethical Committee for Animal Experimentation of the
Faculty of Medicine, University of Geneva and Veteri-
nary Authority in accordance with Swiss guidelines. Ten
female New Zealand white rabbits (six to eight months
old; 3.5±0.5 kg) were purchased from the animal core
facility of the University of Geneva. Rabbits were pre-
medicated with xylazine (Rompun®, Bayer HealthCare
Pharmaceuticals, NJ, USA), and general anaesthesia was
induced and maintained with continuous injection of
ketamine (Ketalar®, Parke-Davis) and acepromazine
(Vetranquil®, Sanofi-Ceva GmbH, Dusseldorf, Ger-
many). In each animal, the MCL was identified, metic-
ulously undermined and a mop-end tear model created
[4, 26]. The ACL was left intact in all experiments. In
fact, we observed in a pilot study that complete ACL
section resulted in disappearance of the ligament after
two weeks (data not shown). Five days after MCL
injury, through an anteromedial skin incision, the in-
jured MCL was identified and exposed for cell trans-
plantation. Through an anteromedial arthrotomy, the
intact ACL was also identified and exposed for cell
transplantation. Rabbit myofibroblasts labelled with
PKH-26 (Sigma, St. Louis, MO, USA) (2×106 cells
per injection in 20 μl DMEM) were injected using a
50-μl syringe with a 27-gauge needle (Hamilton Com-
pany, Bonaduz, Switzerland) into injured MCL and into
intact ACL. Their contralateral knees served as sham-
operated control (20 μl DMEM/no cells). Postoperative-
ly, all animals received daily intramuscular injection of
enrofloxacin for three days (Baytril®, Bayer HealthCare
Pharmaceuticals) and were allowed free cage activity
(cage area: 3 m2). Animals were sacrificed at day one
and day seven postinjection (n05 per group).
Immunohistochemistry
ACL and MCL were retrieved entirely at days one and
seven after surgery, flash frozen, cryosectioned, fixed in
phosphate-buffered saline (PBS)/4% formaldehyde and
observed with a fluorescent microscope (Axiophot
Zeiss) to determine the presence of PKH-26 dyes. Rep-
resentative sections from each ligament were stained
using a mouse monoclonal antibody recognising α-
SMA (clone 1A4, [27]). Briefly, nonspecific sites were
blocked with 5% bovine serum albumin (BSA) in
phosphate-buffered saline for one hour. Sections were
then incubated with anti-α-SMA for one hour, followed
by 30 min incubation with a goat anti-mouse Alexa 488
(Sigma). All nuclei were stained using a fluorescence-
specific 4’-6’-diamidino-2-phenylindole (DAPI) contain-
ing mounting medium (Vector Laboratories, Burlingame,
CA, USA).
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Statistical analysis
Statistical evaluation was performed using Student’s
t test, and results were considered significant if P values
were<0.05.
Results
Primary rabbit fibroblasts differentiate into myofibroblasts
in vitro
Rabbit fibroblasts isolated from the ITB were incubated for
five days with various concentrations of TGF-β1 (0.1, 1 or
10 ng/ml) and analysed by immunofluorescence for α-SMA
expression. With a low dose of TGF-β1 (0.1 or 1 ng/ml) in
culture medium, no difference in α-SMA expression was
observed compared with controls (<10% of α-SMA-
positive cells in all conditions, n04, Fig. 1a, c). A signifi-
cant increase in α-SMA expression was observed when
fibroblasts were incubated with 10 ng/ml of TGF-β1 for
five days (86.4±4.6% of α-SMA-positive cells, n04,
Fig. 1b, c). Moreover, we observed that culture-derived
myofibroblasts maintain their contractile phenotype in vitro
up to five days after cessation of TGF-β1 stimulation (data
not shown).
Autologous transplantation of culture derived myofibroblast
in rabbit ligaments
After five days of incubation with 10 ng/ml of TGF-β1,
myofibroblasts were trypsinised, marked with PHK-26, a
stable lipophilic cell membrane linker, and injected into
intact ACL and injured MCL. Prior to transplantation, α-
SMA expression was confirmed by immunofluorescence
cytospin assay with >80% positive cells (Fig. 1d). At one
day postinjection, we observed the presence of PKH-26-
positive cells in all injured and intact ligaments. The α-
SMA-positive cells were found in the same recipient region
in which PKH-26-positive cells were located (Fig. 2a). We
also observed a few α-SMA+/PKH-26− cells in the dam-
aged MCL. At seven days postinjection (Fig. 2b), the
Fig. 1 Transforming growth factor beta-1 (TGF-β1) at 10 ng/ml for
5 days (b, c) for 5 days significantly increases the proportion of α-
smooth-muscle actin (SMA)-positive fibroblasts (green staining)
compared with untreated cells (a, c). Trypsinisation of rabbit
myofibroblasts after TGF-β1 treatment had no effect on α-SMA
expression as assessed by cytospin assay (d). These data are repre-
sentative of at least four different experiments for each condition
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density of PKH-26-positive cells had decreased in both
ligaments, but colocalisation of α-SMA and PKH-26 was
still observed in the injured MCL.
Myofibroblast as a vehicle for gene therapy
To evaluate the possibility of using myofibroblasts as a
vehicle for therapeutic products, rabbit fibroblasts were
transduced with a lentivirus encoding the GFP marker protein
(>90% of GFP-positive cells) and cultured in the presence of
10 ng/ml TGF-β1 for five days. Alpha-SMA expression was
observed in GFP-positive cells, indicating that lentivirus did
not alter rabbit fibroblast differentiation capacity in vitro
(Fig. 3a). The presence of GFP-positive cells coexpressing
α-SMA in the injection region was confirmed by immunoflu-
orescence one day after transplantation (Fig. 3b).
Fig. 2 PKH-26+cells maintained their myofibroblasts phenotype
in vivo up to 7 days after transplantation in rabbit ligament.
Culture-derived myofibroblasts labelled with PKH-26 (red) were
transplanted in damaged [medial collateral ligaments (MCL)] or
intact [anterior cruciate ligament (ACL)] ligaments, and biopsies
were performed at 1 (a) or 7 (b) days after cell injection. Tissue
sections were analysed using immunofluorescence for α-smooth-
muscle actin (α-SMA) (green) and 4’-6’-diamidino-2-phenylindole
(DAPI) (blue). The sections shown are representative of five
analysed grafts
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Discussion
Cell transplantation for ligament healing relies on the ability
of transplanted cells to retain their intrinsic phenotype in the
context of a massive endogenous inflammation. This study
analysed the fate of rabbit myofibroblasts after autologous
transplantation in intact and injured ligaments. In accor-
dance with previous studies [28], we found that under spe-
cific conditions, fibroblasts from different origins can be
differentiated into myofibroblasts in the presence of TGF-
β1. Myofibroblasts were able to maintain their phenotype
up to five days in vitro after cessation of TGF-β1 (data not
shown). These findings confirm the feasibility of using
cultured myofibroblasts for a cell therapy approach.
The second part of the experiment demonstrated that
myofibroblasts can be transplanted into damaged ligaments
as well as into dense and poorly vascularised tissue, such as
an intact ligament, and survive in such environments. Trans-
planted cells maintain α-SMA expression in the intact and
injured ligament at one day after injection. At seven days
posttransplantation, double-positive cells (α-SMA+/PKH-
26+) were observed in damaged MCL only. The presence
of TGF-β1 within the injured ligament, as recently de-
scribed [24], may create a favourable environment for myo-
fibroblasts in vivo and may explain in part their presence in
injured ligament only at seven days postinjection. It is also
possible that myofibroblasts remain quiescent after trans-
plantation, and in this state, α-SMA turnover is slow and the
cells survive for a long time [29]. Moreover, in addition to
promoting myofibroblast differentiation, it is known that
combined activation of the adhesion-dependent focal adhe-
sion kinase pathway and the soluble growth-factor-mediated
protein kinase B (AKT) pathway confers anoikis/apoptosis
resistance to TGF-β1differentiated myofibroblasts [30].
Despite some study limitations (there is no quantitative
analysis of cell survival postinjection and no evaluation of
the ligament healing process after transplantation), we
believe that this study is novel and provides important initial
information for the use of mechanically active cells as a
source for cell-based therapy. We show evidence that myo-
fibroblasts do not dedifferentiate early after transplantation;
therefore, it appears likely that they become fixed to the
extracellular matrix, a necessary step for the maintenance of
differentiation [31]. Moreover, we show that genetically
modified fibroblasts differentiate into myofibroblasts and
can be transplanted into ligaments. Injection of genetically
modified myofibroblasts expressing growth factors may
stimulate and promote formation of new ligament tissue,
leading to an accelerated recovery. Growth factors such as
epithelial growth factor (EGF), TGF-β1 or platelet-derived
growth factor (PDGF) stimulate fibroblasts to proliferate
and to reconstitute a collagen-rich extracellular matrix
[32, 33].
These findings clearly suggest that cell-therapy approaches
using mechanically active cells such as myofibroblasts may
represent an interesting strategy for improving the healing of
extra- and intra-articular ligaments. Further investigations are
required to unveil the full potency of such an approach.
Fig. 3 Green fluorescent protein (GFP)-transduced fibroblasts main-
tained their capacity to express α-smooth-muscle actin (SMA) in vitro
and in vivo. GFP+ fibroblasts treated with transforming growth factor
beta-1 (TGF-β1) (5 days at 10 ng/ml) were analysed for α-SMA
expression before transplantation (a) and 1 day after transplantation
(b). ACL biopsies were immunostained for α-SMA (red) and the
nuclei marked with 4’-6’-diamidino-2-phenylindole (DAPI) (blue).
Sections shown are representative of three analysed grafts
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